Omalizumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Food Allergy
Conditions
Food Allergy
Trial Timeline
Nov 1, 2019 → Mar 15, 2022
NCT ID
NCT04037176About Omalizumab
Omalizumab is a approved stage product being developed by Novartis for Food Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT04037176. Target conditions include Food Allergy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05424523 | Pre-clinical | Completed |
| NCT05157087 | Pre-clinical | Completed |
| NCT04037176 | Approved | Completed |
| NCT02550106 | Approved | Completed |
| NCT02329223 | Phase 3 | Completed |
| NCT02262130 | Phase 2 | Completed |
| NCT02118987 | Phase 1 | Completed |
| NCT02023151 | Approved | Completed |
| NCT01328886 | Phase 3 | Completed |
| NCT01155700 | Phase 3 | Completed |
| NCT00500539 | Phase 3 | Completed |
| NCT00264849 | Approved | Completed |
| NCT00180011 | Phase 2/3 | Completed |
| NCT00639691 | Approved | Completed |
| NCT00226200 | Pre-clinical | Terminated |
| NCT00482248 | Phase 3 | Completed |
| NCT00482508 | Phase 3 | Completed |
| NCT00046748 | Phase 3 | Completed |
Competing Products
17 competing products in Food Allergy